60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
DUBLIN - Investment firm Citadel Group has disclosed a 1.97% interest in Avadel Pharmaceuticals plc, according to a regulatory filing published Tuesday.
The disclosure, made under Irish Takeover Panel rules, shows Citadel holds interests in 1,920,421 shares representing 1.97% of the biopharmaceutical company. The position includes 1,801,121 owned or controlled shares and additional interests through stock-settled derivatives.
The filing also reveals Citadel maintains short positions equivalent to 2.16% of Avadel's shares, consisting of 626,599 directly shorted shares and additional positions through derivatives.
The disclosure details numerous transactions conducted on October 27, with Citadel both buying and selling Avadel shares at prices ranging from $18.50 to $18.59 per share. The largest single purchase was 60,049 shares at $18.57, while the largest sale was 60,376 shares at the same price point.
The regulatory filing, submitted as a Form 8.3, is required under Irish takeover regulations when an entity holds interests representing 1% or more of a company's securities.
Avadel Pharmaceuticals, headquartered in Ireland, trades on the Nasdaq exchange. The disclosure was made through a Regulatory Information Service statement based on Citadel's position as of October 27, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.